The LZ–SMS formulation used in the present study led to an increase in the percentages of immunomodulatory CD4+CD25+Foxp3+ Treg cells and IL-10+ Breg cells in the SLE mice compared with those in the PBS-treated SLE mice. The gene discussed is FOXP3; the disease is systemic lupus erythematosus.